

Bulletin Number: MSA 21-07

Distribution: All Providers

Issued: May 3, 2021

Subject: COVID-19 Response: Children's Special Health Care Services (CSHCS) Coverage of COVID-19 Vaccine Services and U.S. Food & Drug Administration (FDA) Emergency Use Authorization (EUA) Drugs, Devices, and Biological Products for COVID-19 Prevention and Treatment

Effective: As Indicated

Programs Affected: CSHCS

COVID-19 Vaccine Services for CSHCS Beneficiaries

This policy notifies Michigan Department of Health and Human Services (MDHHS) Medicaid enrolled providers of important information regarding CSHCS coverage of COVID-19 vaccine services as an addition to Bulletin MSA 20-75, COVID-19 Response: Coverage of COVID-19 Vaccine Services. Effective for dates of service on or after December 1, 2020, CSHCS will provide coverage and reimbursement for COVID-19 vaccine services for all beneficiaries who are otherwise uninsured. This is a permanent policy change and does not expire following the termination of the federally declared COVID-19 Public Health Emergency (PHE) conditions.

Detailed information regarding coverage and reimbursement for COVID-19 vaccine administration can be found in Bulletin MSA 20-75, which can be accessed on the MDHHS website at www.michigan.gov/medicaidproviders >> Policy, Letters and Forms. The influenza vaccine will be covered and reimbursed consistent with existing Medicaid policies.

COVID-19 EUA Drugs, Devices, and Biological Products for CSHCS Beneficiaries

Also effective for dates of service on or after December 1, 2020, for the duration of the federally declared COVID-19 PHE, CSHCS will cover FDA EUA drugs, devices, and biological products for COVID-19 prevention and treatment for all CSHCS beneficiaries who are otherwise uninsured. This information is in addition to Bulletin MSA-20-81, COVID-19 Response: Coverage of U.S. Food & Drug Administration (FDA) Emergency Use Authorization (EUA) Drugs, Devices and Biological Products for COVID-19 Prevention and Treatment.

Detailed information regarding coverage and reimbursement for FDA EUA drugs, devices, and biological products for COVID-19 prevention and treatment can be found in Bulletin MSA 20-81, which can be accessed on the MDHHS website at www.michigan.gov/medicaidproviders >> Policy, Letters and Forms, under year 2021.

Public Comment

The public comment portion of the policy promulgation process is being conducted concurrently with the implementation of the change noted in this bulletin. Any interested party wishing to comment on the change may do so by submitting comments to Jennifer Baumann via e-mail at BaumannJ@michigan.gov.

Please include "COVID-19 Response: CSHCS Coverage of COVID-19 Vaccine Services and U.S. Food & Drug Administration (FDA) Emergency Use Authorization (EUA) Drugs, Devices, and Biological Products for COVID-19 Prevention and Treatment" in the subject line.

Comments received will be considered for revisions to the change implemented by this bulletin.

Manual Maintenance

Retain this bulletin until the information is incorporated into the MDHHS Medicaid Provider Manual.

Questions

Any questions regarding this bulletin should be directed to Provider Inquiry, Department of Health and Human Services, P.O. Box 30731, Lansing, Michigan 48909-8231, or e-mailed to ProviderSupport@michigan.gov. When you submit questions, be sure to include your name, affiliation, NPI number, and phone number so you may be contacted if necessary. Typical Providers may phone toll-free 1-800-292-2550. Atypical Providers may phone toll-free 1-800-979-4662.

Approved



Kate Massey, Director
Medical Services Administration